Home > Financial Ratios > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Core EBITDA Growth

    Back to All Ratios
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

GLENMARK PHARMACEUTICALS Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   Core EBITDA Growth(%) 5.79-22.6416.5114.913.55

What is the latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS ?

The latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS is 5.79 based on Mar2024 Consolidated results.
Year Core EBITDA Growth
Mar20245.79
Mar2023-22.64
Mar202216.51
Mar202114.91
Mar20203.55

How is Core EBITDA Growth of GLENMARK PHARMACEUTICALS Trending?

Years Core EBITDA Growth % Change
Mar2024 5.79
Positive
Mar2023 -22.64
Negative
Mar2022 16.51
10.73
Mar2021 14.91
320.00
Mar2020 3.55 -

Other Financial Ratios of GLENMARK PHARMACEUTICALS


Compare Core EBITDA Growth ratio of peers of GLENMARK PHARMACEUTICALS

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS ₹40,842.8 Cr 4.8% 5.2% 40% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹416,273.0 Cr 2.9% 1.8% 14% Stock Analytics
DIVIS LABORATORIES ₹166,750.0 Cr 5.7% 9.6% 58.6% Stock Analytics
CIPLA ₹121,122.0 Cr -0.8% 1.2% 6.2% Stock Analytics
TORRENT PHARMACEUTICALS ₹110,487.0 Cr 0.8% 1.2% 25.4% Stock Analytics
DR REDDYS LABORATORIES ₹102,680.0 Cr 2.9% 6.5% 4.3% Stock Analytics


GLENMARK PHARMACEUTICALS Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS

4.8%

5.2%

40%

SENSEX

3.6%

9.5%

13.3%


You may also like the below Video Courses